

**PHARMACOLOGY BIOCHEMISTRY  
&  
BEHAVIOR**

**Index to  
VOLUME 28 1987**



## SUBJECT INDEX

- Abstinence, 87  
   fluid diet  
   morphine  
   physical dependence  
 Acceptability, 525  
   amino acid analogues  
   drinking  
 Acetylcholine concentration, 157  
   ethylcholine aziridinium  
   extinction  
   learning and memory impairment  
 Acute exposure, 147  
   central nervous system  
   choline uptake  
   noise  
 Adenosine receptors, 179  
   caffeine  
   locomotor activity  
   L-phenylisopropyladenosine  
   strain differences  
 Age differences, 341  
   lighting  
   individual housing  
   phencyclidine  
 Aggression, 503  
   dose-dependent effects  
   monkeys  
   tryptophan  
 Alcohol preference, 105  
   ethanol  
   selective breeding  
   tolerance  
 Alpha-2 agonists, 283  
   CNS depressants  
   neuroleptics  
   opioid antagonists  
   opioid-induced rigidity  
   reversal effects  
   route of administration  
 Amino acid analogues, 525  
   acceptability  
   drinking  
 Amino acids, 15  
   barrel rotation  
   bradykinin analogs  
   intracerebroventricular administration  
   neuropeptides  
 Amphetamine  
   apomorphine, 393  
   ascorbic acid, 381  
   behavioral effects, 423  
   central cholinergic mechanisms, 335  
   conditioned taste aversion, 335  
   cue properties, 251  
   differential involvement, 335  
   dopaminergic/non-dopaminergic  
     substrates, 251  
   dopamine neuronal firing, 393  
   drug interaction, 335  
   electrical stimulation, 251  
   haloperidol, 251  
   investigatory behavior, 393  
   in vivo voltammetry, 381  
   locomotor activity, 393, 423  
   morphine, 335  
   serotonin depletion, 381  
   stereotypy, 423  
   uric acid, 381  
   ventral tegmentum, 251  
 d-Amphetamine, 311  
   brain stimulation reward  
   drug interactions  
   morphine  
   threshold determination  
 Angiotensin II, 947  
   insulin-induced drinking  
   plasma volume  
 Animal model  
   antidepressant-like profiles, 321  
   cerebral embolization, 243  
   discrimination task, 243  
   drug interaction, 321  
   escape failures, 321  
   GABA agonists, 321  
   learned helplessness, 321  
   locomotor activity, 291  
   memory impairment, 243  
   MPTP pretreatment, 291  
   nicotine, 291  
   noradrenergic receptors, 321  
   Parkinson's disease, 291  
   swimming-induced immobility, 321  
 Antidepressant-like profiles, 321  
   animal models  
   drug interaction  
   escape failures  
   GABA agonists  
   learned helplessness  
   noradrenergic receptors  
   swimming-induced immobility  
 Anxiogenic effects, 29  
   light/dark test  
   locomotor activity  
   methyl- $\beta$ -carboline-3-carboxylate  
   RO 15-1788  
 Apomorphine  
   amphetamine, 393  
   climbing behavior, 35  
   D1 binding sites, 477  
   D2 binding sites, 477  
   dopamine neuronal firing, 393  
   dopamine receptor sensitivity, 35  
   investigatory behavior, 393  
   locomotor activity, 393  
   stereotypy, 477  
   up-regulation, 477  
 Apparatus  
   radial arm maze, 157  
   holeboard, 75  
 Arecoline, 275  
   autoimmunity  
   dose-dependent effects  
   motor responses  
   nicotine  
   strain differences  
 Ascorbic acid, 381  
   amphetamine  
   in vivo voltammetry  
   serotonin depletion  
   uric acid  
 Atropine, 375  
   chronic administration  
   dose-dependent effects  
   drug interactions  
   key-pecking behavior  
   physostigmine  
   pigeons  
 Autoimmunity, 275  
   arecoline  
   dose-dependent effects  
   motor responses  
   nicotine  
   strain differences  
 Autotomy, 385  
   deafferentation  
   beta-endorphin concentrations  
   Met-enkephalin concentrations  
   strain differences  
 Baboons, 389  
   cocaine substitution procedure  
   intravenous self-administration  
   phenylpropanolamine  
 Barbiturates, 75  
   benzodiazepine receptor agonist  
   drug interaction  
   exploratory activity  
 Barrel rotation, 15  
   amino acids  
   bradykinin analogs  
   intracerebroventricular administration  
   neuropeptides  
 Basal gastric acid secretion, 419  
   gastric ulcers  
   histidine carboxylase  
   intraluminal pH levels  
 Behavioral analyses, 43  
   drug interaction  
   ethylketocyclazocine  
   locomotor activity  
   naloxone  
 Behavioral development, 411  
   developmental toxicity  
   perinatal phencyclidine  
   prenatal phencyclidine  
 Behavioral effects  
   amphetamine, 423  
   dose-dependent effects, 153  
   drug comparisons, 153  
   N-ethyl-3,4-methylenedioxy-  
     amphetamine, 153  
   locomotor activity, 423  
   stereotypy, 423  
 Behavioral hyperactivity, 469  
   cerebral glucose metabolism  
   choline supplementation  
   chronic administration  
   pentobarbital  
 Behavioral tolerance, 111  
   chronic ethanol tolerance  
   free-choice consumption  
   selective breeding  
 Benzodiazepine receptor agonist, 75  
   barbiturates

- drug interaction
  - exploratory activity
- Benzodiazepine receptor binding, 521
  - GABA
    - in vivo
    - Tyr-MIF-1
- Benzodiazepine receptors, 21
  - brain stimulation, electrical
  - medial hypothalamus
- Benzodiazepines
  - $\beta$ -carbolines, 427
  - eating, 427
  - 5-HT<sub>1A</sub> agonists, 187
  - hypertonic saline consumption, 187
  - palatability, 427
  - rehydration, 187
- Beta-adrenoceptors, 171
  - cardiovascular effects
  - chronic treatment
  - delta-9-tetrahydrocannabinol
- Bradykinin analogs, 15
  - amino acids
  - barrel rotation
  - intracerebroventricular administration
  - neuropeptides
- Brain
  - amygdala, 291
  - bicuculline, 21
  - caudate, 381, 423
  - dorsal hippocampus, 327
  - dorsal raphe nuclei, 327
  - frontal cortex, 147
  - globus pallidus, 381
  - hippocampus 147, 157, 465
  - hypothalamus, 147
  - lateral habenular nuclei, 327
  - lateral hypothalamus, 197, 511
  - medial amygdala, 101
  - median raphe nuclei, 327
  - midbrain central gray, 21
  - neostriatum, 453
  - nucleus accumbens, 423
  - olfactory tubercle, 291
  - prefrontal cortex, 327
  - striatum 35, 147, 291
  - substantia nigra pars reticulata, 453
  - ventral tegmentum, 251, 261
- Brain stimulation, electrical, 21
  - benzodiazepine receptors
  - medial hypothalamus
- Brain stimulation reward, 311
  - d-amphetamine
  - drug interactions
  - morphine
  - threshold determination
- Caffeine, 179
  - adenosine receptors
  - locomotor activity
  - L-phenylisopropyladenosine
  - strain differences
- Capsaicin, 65
  - route of administration
  - substance P release
  - thermoregulation
  - Tween 80
- $\beta$ -Carbolines, 427
  - benzodiazepines
  - eating
  - palatability
- Cardiovascular effects, 171
  - beta-adrenoceptors
  - chronic treatment
  - delta-9-tetrahydrocannabinol
- Cardiovascular responses, 459
  - cocaine
  - drug interaction
  - human studies, males
  - marijuana
- Catalepsy, 453
  - GABA mechanism
  - muscle rigidity
  - substantia nigra pars reticulata
- Central cholinergic mechanisms, 335
  - amphetamine
  - conditioned taste aversion
  - differential involvement
  - drug interaction
  - morphine
- Central mechanism, 401
  - chronic administration
  - cocaine
  - discriminative stimulus properties
  - tolerance
- Central nervous system, 147
  - acute exposure
  - choline uptake
  - noise
- Cerebral embolization, 243
  - animal model for dementia
  - discrimination task
  - memory impairment
- Cerebral glucose metabolism, 469
  - behavioral hyperactivity
  - choline supplementation
  - chronic administration
  - pentobarbital
- Choline supplementation, 469
  - behavioral hyperactivity
  - cerebral glucose metabolism
  - chronic administration
  - pentobarbital
- Choline uptake, 147
  - acute exposure
  - central nervous system
  - noise
- Chronic administration
  - atropine, 375
  - behavioral hyperactivity, 469
  - central mechanism, 401
  - cerebral glucose metabolism, 469
  - choline supplementation, 469
  - cocaine, 401
  - discriminative stimulus properties, 401
  - dose-dependent effects, 375
  - drug interactions, 375
  - key-pecking behavior, 375
  - pentobarbital, 469
  - physostigmine, 375
  - pigeons, 375
  - tolerance, 401
- Chronic ethanol tolerance, 111
  - behavioral tolerance
  - free-choice consumption
  - selective breeding
- Chronic excessive intake, 517
  - cocaine
  - oral self-administration
  - schedule induction
- Chronic treatment, 171
  - beta-adrenoceptors
  - cardiovascular effects
  - delta-9-tetrahydrocannabinol
- Cigarette smoking, 305
  - human studies
  - nicotine intake
  - tobacco smoke refining
- Classical conditioning, 7
  - nitrous oxide
  - skin conductance
- Climbing behavior, 35
  - apomorphine
  - dopamine receptor sensitivity
- CNS depressants, 283
  - alpha-2-agonists
  - neuroleptics
  - opioid antagonists
  - opioid-induced rigidity
  - reversal effects
  - route of administration
- Cocaine
  - cardiovascular responses, 459
  - central mechanism, 401
  - chronic administration, 401
  - chronic excessive intake, 517
  - discriminative stimulus properties, 401
  - drug interaction, 459
  - human studies, male, 459
  - injection speed, 407
  - marijuana, 459
  - minimum reinforcing dose, 407
  - monkeys, crab-eating, 407
  - oral self-administration, 517
  - pentobarbital, 407
  - schedule induction, 517
  - self-administration, 407
  - tolerance, 401
- Cocaine substitution procedure, 389
  - baboons
  - intravenous self-administration
  - phenylpropanolamine
- Cognitive behavior, 213
  - human studies
  - methylphenidate
  - problem solving
- Conditioned place preference
  - drug interaction, 267
  - lateral hypothalamus, 511
  - locomotor activity, 267
  - morphine, 267
  - naltrexone, 267
  - reinforcement, 511
  - substance P, 511
- Conditioned taste aversion
  - amphetamine, 335
  - central cholinergic mechanisms, 335
  - differential involvement, 335
  - drug interaction, 219, 335
  - morphine, 219, 335
  - nicotine, 495
  - opiate antagonist, 219
  - opiate receptors, 219
  - place conditioning, 219
  - route of administration, 495
  - saccharin, 495
- Cue properties
  - amphetamine, 251
  - differential effects, 261
  - discrimination, 261
  - dopaminergic/non-dopaminergic substrates, 251
  - electrical stimulation, 251, 261
  - haloperidol, 251
  - physostigmine, 261
  - ventral tegmentum, 251, 261

- D1 binding sites, 477
  - apomorphine
  - D2 binding sites
  - stereotypy
  - up-regulation
- D2 binding sites, 477
  - apomorphine
  - D1 binding sites
  - stereotypy
  - up-regulation
- Deafferentation, 385
  - autotomy
  - beta-endorphin concentrations
  - Met-enkephalin concentrations
  - strain differences
- Delayed onset, 203
  - escape behavior
  - haloperidol
  - learning
- Depressive behavior, 367
  - desipramine
  - neonatal exposure
  - zimeldine
- Desipramine, 367
  - depressive behavior
  - neonatal exposure
  - zimeldine
- Developmental toxicity, 411
  - behavioral development
  - perinatal phencyclidine
  - prenatal phencyclidine
- Diazepam
  - extinction, 81
  - free recall, 347
  - human studies, 347
  - memory, explicit, 347
  - memory, implicit, 347
  - monkeys, 81
  - neurological impairment, 347
  - self-administration, 81
  - spared memory function, 347
  - word completion, 347
- Differential effects, 261
  - cue properties
  - discrimination
  - electrical stimulation
  - physostigmine
  - ventral tegmentum
- Differential involvement, 335
  - amphetamine
  - central cholinergic mechanisms
  - conditioned taste aversion
  - drug interaction
  - morphine
- Diisopropylphosphofluoridate, 317
  - genetic variation
  - inbred mice
  - paraoxonase activity
- 2,5-Dimethoxy-4-methylamphetamine, 327
  - dose-dependent effects
  - hallucinogens
  - intracranial administration
  - operant behavior
- Discrimination, 261
  - cue properties
  - differential effects
  - electrical stimulation
  - physostigmine
  - ventral tegmentum
- Discrimination task, 243
  - animal model for dementia
  - cerebral embolism
  - memory impairment
- Discriminative stimulus properties, 401
  - central mechanism
  - chronic administration
  - cocaine
  - tolerance
- Dopamine neuronal firing, 393
  - amphetamine
  - apomorphine
  - investigatory behavior
  - locomotor activity
- Dopamine receptor sensitivity, 35
  - apomorphine, 35
  - climbing behavior, 35
  - hypothyroidism, 193
  - post-synaptic changes, 193
- Dopaminergic/non-dopaminergic substrates, 251
  - amphetamine
  - cue properties
  - electrical stimulation
  - haloperidol
  - ventral tegmentum
- Dose-dependent effects
  - aggression, 503
  - arecoline, 275
  - atropine, 375
  - autoimmunity, 275
  - behavioral effects, 153
  - chronic administration, 375
  - 2,5-dimethoxy-4-methylamphetamine, 327
  - drug comparisons, 153
  - drug interactions, 375
  - N-ethyl-3,4-methylenedioxyamphetamine, 153
  - hallucinogens, 327
  - intracranial administration, 327
  - key-pecking behavior, 375
  - mephenytoin, 483
  - methsuximide, 483
  - monkeys, 503
  - motor responses, 275
  - nicotine, 275
  - operant behavior, 327
  - physostigmine, 375
  - pigeons, 375, 483
  - repeated acquisition, 483
  - strain differences, 275
  - tryptophan, 503
- Drinking
  - acceptability, 525
  - amino acid analogues, 525
  - ethanol, 437
  - NaCl intake, 209
  - repeated administration, 209
  - reserpine, 209
  - social structure, 437
  - stress, 437
  - tolerance, 209
- Drug
  - amphetamine 219, 251, 335, 381, 393, 423
  - d-amphetamine, 311
  - anti-dynorphin B antiserum, 465
  - apomorphine 35, 393, 477
  - arecoline, 275, 433
  - atropine, 15, 335, 375, 433
  - B4162, 15
  - baclofen, 283
  - bicuculline, 433
  - buprenorphine, 283
  - buspiron hydrochloride, 1
  - caffeine, 179
  - capsaicin, 65, 219
  - captopril, 15
  - carbidopa, 283
  - chlomipramine, 385
  - chlorazepate, 29
  - p-chlorophenylalanine, 381
  - m-chlorophenylpiperazine hydrochloride, 1
  - choline, 469
  - clonidine, 235, 443
  - cocaine, 81, 389, 401, 407, 459, 517
  - 2-deoxy glucose, 71
  - desipramine, 367
  - dexamethasone, 443
  - diazepam, 15, 75, 81, 283, 347
  - diethyl ether, 283
  - diisopropylphosphofluoridate, 317
  - dimaprit, 283
  - droperidol, 283
  - ephedrine, 361
  - ethanol, 53, 57, 75, 105, 111, 437
  - ethylcholine aziridinium, 157
  - ethylketocyclazocine, 43, 489
  - fenfluramine, 1
  - fentanyl, 283
  - fluoxetine, 1
  - flurothyl, 165
  - FMHd, 419
  - FMHm, 419
  - gamma-acetylenic GABA, 283
  - geprione, 187
  - guanethidine, 283
  - guanfacine, 283
  - haloperidol, 15, 35, 175, 203, 251, 283, 423, 477
  - 6-hydroxydopamine, 197
  - 8-hydroxy-2(di-n-propylamine)-tetra-line hydrobromide, 1
  - idazoxan, 283
  - imipramine, 321
  - ipsapirone, 187
  - 3-isobutyl-1-methylxanthine, 235
  - isoflurane, 283
  - ketanserin, 353
  - ketocyclazocine, 71
  - kojic amine, 283
  - lithium chloride, 219, 335
  - marijuana, 459
  - MDA, 39
  - MDMA, 39
  - mecamylamine, 275
  - mephenytoin, 483
  - metergoline, 1
  - methadone, 87
  - methohexital, 283
  - 5-methoxy-N-N-dimethyltryptamine hydrogen oxalate, 1
  - methsuximide, 483
  - methyl-atropine, 335
  - methyl- $\beta$ -carboline-3-carboxylate, 29
  - 3,4-methylenedioxymethamphetamine, 153
  - N-methyl-3,4-methylenedioxyamphetamine, 153
  - methylnaltrexone, 219
  - methylphenidate, 213
  - 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 291
  - methysergide, 283

- methiamide, 283
- mianserin, 353
- midazolam, 21, 187, 427
- MK-212, 433
- monosodium glutamate, 165
- morphine, 87, 95, 197, 219, 227, 267, 283, 311, 335
- Mr2266, 227
- Mr2267, 227
- muscimol, 15, 321
- naloxone, 15, 43, 87, 165, 227, 235
- naltrexone, 95, 147, 219, 267
- naltrexone methyl bromide, 283
- nicotine, 275, 291, 305, 495
- nitrous oxide, 7
- noradrenaline, 101
- 8-OH-DPAT, 187
- pancuronium, 283
- penbutolol, 321
- pentobarbital, 371, 407, 433, 469
- phencyclidine, 341, 411, 489
- phenobarbital, 15
- phentolamine, 283
- phenylephrine, 433
- L-phenylisopropyladenosine, 179
- phenylpropanolamine, 71, 389
- phenytoin, 15
- physostigmine, 261, 375
- picrotoxin, 321, 443, 453
- piperoxane, 283
- pirenperone, 1, 39, 353
- prazosin, 283, 321
- progabide, 283, 443
- reserpine, 209, 477
- R16-6028, 427
- RO 15-1788, 21,29
- Ro 15-4513, 75
- Ro 17-1812, 427
- Ro23-0364, 187
- SCH 23390, 477
- scopolamine, 275
- SKF 10,047, 489
- sodium nitroprusside, 283
- sodium pentobarbital, 75
- sodium valproate, 47
- suriclone, 427
- $\Delta^9$ -tetrahydrocannabinol, 171
- tetrahydro- $\beta$ -carboline, 1
- THIP, 21
- 1-(m-trifluoromethylphenyl)piperazinehydrochloride, 1
- Tween 80, 65
- U50,488, 227
- zimeldine, 367
- ZK 91296, 427
- ZK 93423, 427
- Drug comparisons, 153
  - behavioral effects
  - dose-dependent effects
  - N-ethyl-3,4-methylenedioxyamphetamine
- Drug discrimination
  - 5HT agonists, 1
  - 5HT receptors, 1
  - pentobarbital, 371
  - progesterone stimulus properties, 371
  - sex differences, 371
  - tetrahydro- $\beta$ -carboline, 1
- Drug interaction
  - amphetamine, 335
  - d-amphetamine, 311
  - animal models, 321
  - antidepressant-like profiles, 321
  - atropine, 375
  - barbiturates, 75
  - behavioral analyses, 43
  - benzodiazepine receptor agonists, 75
  - brain stimulation reward, 311
  - cardiovascular responses, 459
  - central cholinergic mechanisms, 335
  - chronic administration, 375
  - cocaine, 459
  - conditioned place preference, 267
  - conditioned taste aversion, 219, 335
  - differential involvement, 335
  - dose-dependent effects, 375
  - $\beta$ -endorphin, 197
  - escape failures, 321
  - ethylketocyclazocine, 43, 489
  - exploratory activity, 75
  - fluoroethyl, 165
  - GABA agonists, 321
  - human studies, males, 459
  - hypothermia, 165
  - key-pecking behavior, 375
  - lateral hypothalamus, 197
  - learned helplessness, 321
  - locomotor activity, 43, 267
  - marijuana, 459
  - MDA, 39
  - MDMA, 39
  - methylxanthines, 235
  - morphine, 197, 219, 267, 311, 335, 197
  - motor performance, 197
  - naloxone, 43, 197
  - naltrexone, 43, 267
  - neonatal monosodium glutamate, 165
  - noradrenergic receptors, 321
  - operant behavior suppression, 235
  - operant responding, 39
  - opiate antagonist, 219
  - opiate receptors, 219
  - opiate withdrawal, 235
  - phencyclidine, 489
  - physostigmine, 375
  - pigeons, 375
  - pirenperone, 39
  - place conditioning, 219
  - seizure thresholds, 165
  - SKF 10,047, 489
  - stereotyped behavior, 489
  - swimming-induced immobility, 321
  - threshold determination, 311
- Dynorphinergic mechanisms, 465
  - exploratory behavior
  - hippocampus
  - inbred mice
  - strain differences
- Eating, 427
  - benzodiazepines
  - $\beta$ -carbolines
  - palatability
- Electrical stimulation
  - amphetamine, 251
  - cue properties, 251, 261
  - differential effects, 261
  - discrimination, 261
  - dopaminergic/non-dopaminergic substrates, 251
  - haloperidol, 251
  - physostigmine, 261
  - ventral tegmentum, 251, 261
- Electrode location, 291
  - estradiol
  - ovariectomy
  - rats, females
  - seizures, amygdala-kindled
- Endogenous opioids, 95
  - footshock
  - hyperthermia
  - thermoregulation
- $\beta$ -Endorphin, 197
  - drug interaction
  - lateral hypothalamus
  - morphine
  - motor performance
  - naloxone
- $\beta$ -Endorphin concentrations, 385
  - autotomy
  - deafferentation
  - Met-enkephalin concentrations
  - strain differences
- Met-Enkephalin concentrations, 385
  - autotomy
  - beta-endorphin concentrations
  - deafferentation
  - strain differences
- Ephedrine, 361
  - exercise enhancement
  - human studies
  - maximal aerobic capacity
  - perceived exertion
  - sympathomimetics
- Escape behavior, 203
  - delayed onset
  - haloperidol
  - learning
- Escape failures, 321
  - animal models
  - antidepressant-like profiles
  - drug interaction
  - GABA agonists
  - learned helplessness
  - noradrenergic receptors
  - swimming-induced immobility
- Estradiol, 291
  - electrode location
  - ovariectomy
  - rats, females
  - seizures, amygdala-kindled
- Ethanol
  - alcohol preference, 105
  - drinking, 437
  - latent inhibition, 53, 57
  - selective breeding, 105
  - self-administration, 53, 57
  - social structure, 437
  - strain differences, 53
  - stress, 437
  - taste aversion learning, 53, 57
  - tolerance persistence, 105
- Ethylcholine aziridinium, 157
  - acetylcholine concentration
  - extinction
  - learning and memory impairment
- Ethylketocyclazocine
  - behavioral analyses, 43
  - drug interaction, 43, 489
  - locomotor activity, 43
  - naloxone, 43
  - phencyclidine, 489
  - SKF 10,047, 489
  - stereotyped behavior, 489
- Exercise enhancement, 361

- ephedrine
  - human studies
  - maximal aerobic capacity
  - perceived exertion
  - sympathomimetics
- Exploratory activity
  - barbiturates, 75
  - benzodiazepine receptor agonist, 75
  - drug interaction, 75
  - dynorphinergic mechanisms, 465
  - hippocampus, 465
  - inbred mice, 465
  - strain differences, 465
- Extinction
  - acetylcholine concentration, 157
  - diazepam, 81
  - ethylcholine aziridinium, 157
  - learning and memory impairment, 157
  - monkeys, 81
  - self-administration, 81
- Fighting, 341
  - age differences
  - individual housing
  - phencyclidine
- Fluid diet, 87
  - abstinence
  - morphine
  - physical dependence
- Flurothyl, 165
  - drug interaction
  - hypothermia
  - neonatal monosodium glutamate seizure thresholds
- Food intake, 71
  - hyperphagia
  - phenylpropanolamine
- Footshock, 95
  - endogenous opioids
  - hyperthermia
  - thermoregulation
- Free-choice consumption, 111
  - behavioral tolerance
  - chronic ethanol tolerance
  - selective breeding
- Free recall, 347
  - diazepam
  - human studies
  - memory, explicit
  - memory, implicit
  - neurological impairment
  - spared memory function
  - word completion
- GABA, 521
  - benzodiazepine receptor binding
  - in vivo
  - Tyr-MIF-1
- GABA agonists, 321
  - animal models
  - antidepressant-like profiles
  - drug interaction
  - escape failures
  - learned helplessness
  - noradrenergic receptors
  - swimming-induced immobility
- GABA mechanisms, 453
  - catalepsy
  - muscle rigidity
  - substantia nigra pars reticulata
- GABA transaminase inhibitors, 47
  - locomotor activity
  - sexual behavior, male rat
- Gastric ulcers, 419
  - basal gastric acid secretion
  - histidine carboxylase
  - intraluminal pH levels
- Genetic variation, 317
  - diisopropylphosphofluoridate
  - inbred mice
  - paraoxonase activity
- Hallucinogens, 327
  - 2,5-dimethoxy-4-methylamphetamine
  - dose-dependent effects
  - intracranial administration
  - operant behavior
- Haloperidol
  - amphetamine, 251
  - cue properties, 251
  - delayed onset, 203
  - dopaminergic/non-dopaminergic substrates, 251
  - electrical stimulation, 251
  - escape behavior, 203
  - learning, 203
  - oral movement, 175
  - tolerance, 175
  - treatment duration, 175
  - ventral tegmentum, 251
- Hippocampal choline uptake, 433
  - intraseptal drug injection
  - pentobarbital-induced narcosis
- Hippocampus, 465
  - dynorphinergic mechanisms
  - exploratory behavior
  - inbred mice
  - strain differences
- Histidine carboxylase, 419
  - basal gastric acid secretion
  - gastric ulcer
  - intraluminal pH levels
- Hormone
  - estradiol, 291
  - insulin, 447
  - progesterone, 371
- 5HT agonists, 1
  - drug discrimination
  - 5HT receptors
  - tetrahydro- $\beta$ -carboline
- 5HT receptors, 1
  - drug discrimination
  - 5HT agonists
  - tetrahydro- $\beta$ -carboline
- 5-HT<sub>1A</sub> agonists, 187
  - benzodiazepines
  - hypertonic saline consumption
  - rehydration
- Human studies
  - cigarette smoking, 305
  - cognitive behavior, 213
  - diazepam, 347
  - ephedrine, 361
  - exercise enhancement, 361
  - free recall, 347
  - maximal aerobic capacity, 361
  - memory, explicit, 347
  - memory, implicit, 347
  - methylphenidate, 213
  - neurological impairment, 347
  - nicotine intake, 305
  - perceived exertion, 361
  - problem solving, 213
  - spared memory function, 347
  - sympathomimetics, 361
  - tobacco smoke refining, 305
  - word completion, 347
- Human studies, males, 349
  - cardiovascular responses
  - cocaine
  - drug interaction
  - marijuana
- Hyperphagia, 71
  - food intake
  - phenylpropanolamine
- Hyperthermia, 95
  - endogenous opioids
  - footshock
  - thermoregulation
- Hypertonic saline consumption, 187
  - benzodiazepines
  - 5-HT<sub>1A</sub> agonists
  - rehydration
- Hypothermia, 165
  - drug interaction
  - flurothyl
  - neonatal monosodium glutamate seizure thresholds
- Hypothyroidism, 193
  - dopamine receptor sensitivity
  - post-synaptic changes
- Inbred mice
  - diisopropylphosphofluoridate, 317
  - dynorphinergic mechanisms, 465
  - exploratory behavior, 465
  - genetic variation, 465
  - hippocampus, 465
  - paraoxonase activity, 317
  - strain differences, 465
- Individual housing, 341
  - age differences
  - fighting
  - phencyclidine
- Injection speed, 407
  - cocaine
  - minimum reinforcing dose
  - monkeys, crab-eating
  - pentobarbital
  - self-administration
- Insulin-induced drinking, 447
  - angiotensin II
  - plasma volume
- Intracerebroventricular administration, 15
  - amino acids
  - barrel rotation
  - bradykinin analogs
  - neuropeptides
- Intracranial administration, 327
  - 2,5-dimethoxy-4-methylamphetamine
  - dose-dependent effects
  - hallucinogens
  - operant behavior
- Intraluminal pH levels, 419
  - basal gastric acid secretion
  - gastric ulcers
  - histidine carboxylase
- Intraseptal drug injection, 433
  - hippocampal choline uptake
  - pentobarbital-induced narcosis

- Intravenous self-administration, 389
  - baboons
  - cocaine
  - phenylpropranolamine
- Investigatory behavior, 393
  - amphetamine
  - apomorphine
  - dopamine neuronal firing
  - locomotor activity
- In vivo, 521
  - benzodiazepine receptor binding
  - GABA
  - Tyr-MIF-1
- In vivo voltammetry, 381
  - amphetamine
  - ascorbic acid
  - serotonin depletion
  - uric acid
- Kappa receptors, 227
  - opiate aversions
  - place conditioning
- Key-pecking behavior, 375
  - atropine
  - chronic administration
  - dose-dependent effects
  - drug interactions
  - physostigmine
  - pigeons
- Latent inhibition
  - ethanol, 53, 57
  - self-administration, 53, 57
  - strain differences, 57
  - taste aversion learning, 53, 57
- Lateral hypothalamus
  - conditioned place preference, 511
  - drug interaction, 197
  - $\beta$ -endorphin, 197
  - morphine, 197
  - motor performance, 197
  - naloxone, 197
  - reinforcement, 511
  - substance P, 511
- Learned helplessness, 321
  - animal models
  - antidepressant-like profiles
  - drug interaction
  - escape failures
  - GABA agonists
  - noradrenergic receptors
  - swimming-induced immobility
- Learning, 203
  - delayed onset
  - escape behavior
  - haloperidol
- Learning and memory impairment, 157
  - acetylcholine concentration
  - ethylcholine aziridinium
  - extinction
- Light/dark test, 29
  - anxiogenic effects
  - locomotor activity
  - methyl- $\beta$ -carboline-3-carboxylate
  - RO 15-1788
- Locomotor activity
  - adenosine receptors, 179
  - animal model, 291
  - anxiogenic effects, 29
  - amphetamine, 393, 423
  - apomorphine, 393
  - behavioral analyses, 43
  - behavioral effects, 423
  - caffeine, 179
  - conditioned place preference, 267
  - dopamine neuronal firing, 393
  - drug interaction, 43, 393
  - ethylketocyclazocine, 43, 393
  - GABA transaminase inhibitors, 47
  - investigatory behavior, 393
  - light/dark test, 29
  - methyl- $\beta$ -carboline-3-carboxylate, 29
  - morphine, 267
  - MPTP pretreatment, 291
  - naloxone, 43
  - naltrexone, 267
  - nicotine, 291
  - Parkinson's disease, 291
  - L-phenylisopropyladenosine, 179
  - RO 15, 1788, 29
  - sexual behavior, male rat, 47
  - strain differences, 179
  - stereotypy, 423
- Marijuana, 459
  - cardiovascular responses
  - cocaine
  - drug interaction
  - human studies, males
- Maximal aerobic capacity, 361
  - ephedrine
  - exercise enhancement
  - human studies
  - perceived exertion
  - sympathomimetics
- MDA, 39
  - drug interactions
- MDMA
  - operant responding
- MDMA, 39
  - drug interactions
- MDA
  - operant responding
- MDA
  - operant responding
- Medial hypothalamus, 21
  - benzodiazepine receptors
  - brain stimulation
- Memory, 353
  - passive avoidance retention
  - serotonergic antagonists
- Memory, explicit, 347
  - diazepam
  - free recall
  - human studies
  - memory, implicit
  - neurological impairment
  - spared memory function
  - word completion
- Memory impairment, 243
  - animal model for dementia
  - cerebral embolism
  - discrimination task
- Memory, implicit, 347
  - diazepam
  - free recall
  - human studies
  - memory, explicit
  - neurological impairment
  - spared memory function
  - word completion
- Mephenytoin, 483
  - dose-dependent effects
  - methsuximide
  - pigeons
  - repeated acquisition
- Methsuximide, 483
  - dose-dependent effects
  - mephenytoin
  - pigeons
  - repeated acquisition
- Methyl- $\beta$ -carboline-3-carboxylate, 29
  - anxiogenic effects
  - light/dark test
  - locomotor activity
  - RO 15-1788
- Methylphenidate, 213
  - cognitive behavior
  - human studies
  - problem solving
- Methylxanthines, 235
  - drug interaction
  - operant behavior
  - opiate withdrawal
- Minimum reinforcing dose, 407
  - cocaine
  - injection speed
  - monkeys, crab-eating
  - pentobarbital
  - self-administration
- Monkeys
  - aggression, 503
  - diazepam, 81
  - dose-dependent effects, 503
  - extinction, 81
  - self-administration, 81
  - tryptophan, 503
- Monkeys, crab-eating, 407
  - cocaine
  - injection speed
  - minimum reinforcing dose
  - pentobarbital
  - self-administration
- Morphine
  - abstinence, 87
  - amphetamine, 335
  - d-amphetamine, 311
  - brain stimulation reward, 311
  - central cholinergic mechanisms, 335
  - conditioned place preference, 267
  - conditioned taste aversion, 219, 335
  - differential involvement, 335
  - drug interactions, 197, 219, 267, 311
  - $\beta$ -endorphin, 197
  - fluid diet, 87
  - lateral hypothalamus, 197
  - locomotor activity, 267
  - morphine, 335
  - motor performance, 197
  - naloxone, 197
  - naltrexone, 267
  - opiate antagonist, 219
  - opiate receptors, 219
  - physical dependence, 87
  - place conditioning, 219
  - threshold determination, 311
- Motor performance, 197
  - drug interaction
  - $\beta$ -endorphin
  - lateral hypothalamus
  - morphine
  - naloxone
- Motor responses, 275



- arecoline
- autoimmunity
- dose-dependent effects
- nicotine
- strain differences
- MPTP pretreatment, 291
  - animal model
  - locomotor activity
  - nicotine
  - Parkinson's disease
- Muricide, 101
  - neuropeptide Y
  - noradrenaline
  - olfactory bulbectomy
- Muscle rigidity, 453
  - catalepsy
  - GABA mechanisms
  - substantia nigra pars reticulata
  
- NaCl intake, 209
  - repeated administration
  - reserpine
  - tolerance
- Naloxone
  - behavioral analyses, 43
  - drug interaction, 43, 197
  - $\beta$ -endorphin, 197
  - ethylketocyclazocine, 43
  - lateral hypothalamus, 197
  - morphine, 197
  - motor performance, 197
- Naltrexone, 267
  - conditioned place preference
  - drug interaction
  - locomotor activity
  - morphine
- Neonatal exposure, 367
  - depressive behavior
  - desipramine
  - zimeldine
- Neonatal monosodium glutamate, 165
  - drug interaction
  - flurothyl
  - hypothermia
  - seizure thresholds
- N-ethyl-3,4-methylenedioxyamphetamines, 153
  - behavioral effects
  - dose-dependent effects
  - drug comparisons
- Neuroleptics, 283
  - alpha-2 agonists
  - CNS depressants
  - opioid antagonists
  - opioid-induced rigidity
  - reversal effects
  - route of administration
- Neurological impairment, 347
  - diazepam
  - free recall
  - human studies
  - memory, explicit
  - memory, implicit
  - spared memory function
  - word completion
- Neuropeptide Y
  - muricide
  - noradrenaline
  - olfactory bulbectomy
- Neuropeptides, 15
  - amino acids
- barrel rotation
- bradykinin analogs
- intracerebroventricular administration
- Nicotine
  - animal model, 291
  - arecoline, 275
  - autoimmunity, 275
  - conditioned taste aversion, 495
  - dose-dependent effects, 275
  - locomotor activity, 291
  - motor responses, 275
  - MPTP pretreatment, 291
  - Parkinson's disease, 291
  - route of administration, 495
  - saccharin, 495
  - strain differences, 275
- Nicotine intake, 305
  - cigarette smoking
  - human studies
  - tobacco smoke refining
- Nitrous oxide, 7
  - classical conditioning
  - skin conductance
- Noise, 147
  - acute exposure
  - central nervous system
  - choline uptake
- Noradrenaline, 101
  - muricide
  - neuropeptide Y
  - olfactory bulbectomy
- Noradrenergic receptors, 321
  - animal models
  - antidepressant-like profiles
  - drug interaction
  - escape failures
  - GABA agonists
  - learned helplessness
  - swimming-induced immobility
- Olfactory bulbectomy, 101
  - muricide
  - neuropeptide Y
  - noradrenaline
- Operant behavior, 327
  - 2,5-dimethoxy-4-methylamphetamine
  - dose-dependent effects
  - hallucinogens
  - intracranial administration
- Operant behavior suppression, 235
  - drug interaction
  - methylxanthines
  - opiate withdrawal
- Operant responding, 39
  - drug interactions
  - MDA
  - MDMA
  - pirenperone
- Opiate antagonist, 219
  - conditioned taste aversion
  - drug interaction
  - morphine
  - opiate receptors
  - place conditioning
- Opiate aversions, 227
  - kappa receptors
  - opiate aversions
- Opiate receptors, 219
  - conditioned taste aversion
  - drug interaction
  - morphine
- opiate antagonist
- place conditioning
- Opiate withdrawal, 235
  - drug interaction
  - methylxanthines
  - operant behavior suppression
- Opioid antagonists, 283
  - alpha-2 agonists
  - CNS depressants
  - neuroleptics
  - opioid-induced rigidity
  - reversal effects
  - route of administration
- Opioid-induced rigidity, 283
  - alpha-2 agonists
  - CNS depressants
  - neuroleptics
  - opioid antagonists
  - reversal effects
  - route of administration
- Oral movement, 175
  - haloperidol
  - tolerance
  - treatment duration
- Oral self-administration, 517
  - chronic excessive intake
  - cocaine
  - schedule induction
- Ovariectomy, 291
  - electrode location
  - estradiol
  - rats, females
  - seizures, amygdala-kindled
  
- Palatability, 427
  - benzodiazepines
  - $\beta$ -carbolines
  - eating
- Paraoxonase activity, 317
  - diisopropylphosphofluoridate
  - genetic variation
  - inbred mice
- Parkinson's disease, 291
  - animal model
  - locomotor activity
  - MPTP pretreatment
  - nicotine
- Passive avoidance retention, 353
  - memory
  - serotonergic antagonists
- Pentobarbital
  - behavioral hyperactivity, 469
  - cerebral glucose metabolism, 469
  - choline supplementation, 369
  - chronic administration, 469
  - cocaine, 407
  - drug discrimination, 371
  - injection speed, 407
  - minimum reinforcing dose, 407
  - monkeys, crab-eating, 407
  - progesterone stimulus properties, 371
  - self-administration, 407
  - sex differences, 371
- Pentobarbital-induced narcosis, 433
  - hippocampal choline uptake
  - intraseptal drug injection
- Peptide
  - angiotensin II, 447
  - bradykinin, 15
  - $\beta$ -endorphin, 197, 385
  - Met-enkephalin, 385

- neuropeptide Y, 101
- substance P, 511
- Perceived exertion, 361
  - ephedrine
  - exercise enhancement
  - human studies
  - maximal aerobic capacity
  - sympathomimetics
- Perinatal phencyclidine, 411
  - behavioral development
  - developmental toxicity
  - prenatal phencyclidine
- Phencyclidine
  - age differences, 341
  - drug interactions, 489
  - ethylketocyclazocine, 489
  - fighting, 341
  - individual housing, 341
  - SKF 10,047, 489
  - stereotyped behavior, 489
- L-Phenylisopropyladenosine, 179
  - adenosine receptors
  - caffeine
  - locomotor activity
  - strain differences
- Phenylpropanolamine
  - baboons, 389
  - cocaine substitution procedure, 389
  - food intake, 71
  - hyperphagia, 71
  - intravenous self-administration, 389
- Physical dependence, 87
  - abstinence
  - fluid diet
  - morphine
- Physostigmine
  - atropine, 375
  - chronic administration, 375
  - cue properties, 261
  - differential effects, 261
  - discrimination, 261
  - dose-dependent effects, 375
  - drug interactions, 375
  - electrical stimulation, 261
  - key-pecking behavior, 375
  - pigeons, 375
  - ventral tegmentum, 261
- Pigeons
  - atropine, 375
  - chronic administration, 375
  - dose-dependent effects, 375, 483
  - drug interactions, 375
  - key-pecking behavior, 375
  - mephentoin, 483
  - methsuximide, 483
  - physostigmine, 375
  - repeated acquisition, 483
- Pirenperone, 39
  - drug interactions
  - MDA
  - MDMA
  - operant responding
- Place conditioning
  - conditioned taste aversion, 219
  - drug interaction, 219
  - kappa receptors, 227
  - morphine, 219
  - opiate antagonist, 219
  - opiate aversions, 227
  - opiate receptors, 219
- Plasma corticosterone levels, 443
  - progabide
  - stress, ether
- Plasma volume, 447
  - angiotensin II
  - insulin induced drinking
- Post-synaptic changes, 193
  - dopamine receptor sensitivity
  - hypothyroidism
- Prenatal development, 411
  - behavioral development
  - developmental toxicity
  - perinatal toxicity
- Problem solving, 213
  - cognitive behavior
  - human studies
  - methylphenidate
- Progabide, 443
  - plasma corticosterone levels
  - stress, ether
- Progesterone stimulus properties, 371
  - drug discrimination
  - pentobarbital
- Rats, females, 291
  - electrode location
  - estradiol
  - ovariectomy
  - seizures, amygdala-kindled
- Rehydration, 187
  - benzodiazepines
  - 5-HT agonists
  - hypertonic saline consumption
- Reinforcement, 511
  - conditioned place preference
  - lateral hypothalamus
  - substance P
- Repeated acquisition, 483
  - dose-dependent effects
  - mephentoin
  - methsuximide
  - pigeons
- Repeated administration, 209
  - NaCl intake
  - reserpine
  - tolerance
- Reserpine, 209
  - NaCl intake
  - repeated administration
  - tolerance
- Reversal effects, 283
  - alpha-2 agonists
  - CNS depressants
  - neuroleptics
  - opioid antagonists
  - opioid-induced rigidity
  - route of administration
- RO 15-1788, 29
  - anxiogenic effects
  - light/dark test
  - locomotor activity
  - methyl- $\beta$ -carboline-3-carboxylate
- Route of administration
  - alpha-2 agonists, 283
  - capsaicin, 65
  - CNS depressants, 283
  - conditioned taste aversion, 495
  - neuroleptics, 283
  - nicotine, 495
  - opioid antagonists, 283
  - opioid-induced rigidity, 283
  - reversal effects, 283
  - saccharin, 495
- substance P release, 65
- thermoregulation, 65
- Tween 80, 65
- Saccharin, 495
  - conditioned taste aversion
  - nicotine
  - route of administration
- Schedule induction, 517
  - chronic excessive intake
  - cocaine
  - oral self-administration
- Seizure thresholds, 165
  - drug interaction
  - flurothyl
  - hypothermia
  - neonatal monosodium glutamate
- Seizures, amygdala-kindled
  - electrode location
  - estradiol
  - ovariectomy
  - rats, females
- Selective breeding
  - alcohol preference, 105
  - behavioral tolerance, 111
  - chronic ethanol tolerance, 111
  - ethanol, 105
  - free-choice consumption, 111
  - tolerance persistence, 105
- Self-administration
  - cocaine, 407
  - diazepam, 81
  - ethanol, 53, 57
  - extinction, 81
  - injection speed, 407
  - latent inhibition, 53, 57
  - minimum reinforcing dose, 407
  - monkeys, 81
  - monkeys, crab-eating, 407
  - pentobarbital, 407
  - strain differences, 57
  - taste aversion learning, 53, 57
- Serotonergic antagonists, 353
  - memory
  - passive avoidance retention
  - sex differences
- Serotonin depletion, 381
  - amphetamine
  - ascorbic acid
  - in vivo voltammetry
  - uric acid
- Sex differences, 371
  - drug discrimination
  - pentobarbital
  - progesterone
- Sexual behavior, male rat
  - GABA transaminase inhibitors
  - locomotor activity
- SKF 10,047
  - drug interactions
  - ethylketocyclazocine
  - phencyclidine
  - stereotyped behavior
- Skin conductance, 7
  - classical conditioning
  - nitrous oxide
- Social structure, 437
  - drinking
  - ethanol
  - stress
- Spared memory function, 347

- diazepam
  - free recall
  - human studies
  - memory, explicit
  - memory, implicit
  - neurological impairment
  - word completion
- Stereotypy
  - amphetamine, 423
  - apomorphine, 477
  - behavioral effects, 423
  - D1 binding sites, 477
  - D2 binding sites, 477
  - drug interactions, 489
  - ethylketocyclazocine, 489
  - locomotor activity, 423
  - phencyclidine, 489
  - SKF 10,047, 489
  - up-regulation, 477
- Strain differences
  - adenosine receptors, 179
  - arecoline, 275
  - autoimmunity, 275
  - autotomy, 385
  - caffeine, 179
  - deafferentation, 385
  - dose-dependent effects, 275
  - dynorphinergic mechanisms, 465
  - beta-endorphin concentrations, 385
  - Met-enkephalin concentrations, 385
  - ethanol, 57
  - exploratory behavior, 465
  - hippocampus, 465
  - inbred mice, 465
  - latent inhibition, 57
  - locomotor activity, 179
  - motor responses, 275
  - nicotine, 275
  - L-phenylisopropyladenosine, 179
  - self-administration, 57
  - taste aversion learning, 57
- Stress, 437
  - drinking
  - ethanol
  - social structure
- Stress, ether, 443
  - plasma corticosterone levels
  - progabide
- Substance P, 511
  - conditioned place preference
  - lateral hypothalamus
  - reinforcement
- Substance P release, 65
  - capsaicin
  - route of administration
  - thermoregulation
  - Tween 80
- Substantia nigra pars reticulata, 453
  - catalepsy
  - GABA mechanisms
- muscle rigidity
- Swimming-induced immobility, 321
  - animal models
  - antidepressant-like profiles
  - drug interaction
  - escape failures
  - GABA agonists
  - learned helplessness
  - noradrenergic receptors
- Sympathomimetics, 361
  - ephedrine
  - exercise enhancement
  - human studies
  - maximal aerobic capacity
  - perceived exertion
- Taste aversion learning
  - ethanol, 53, 57
  - latent inhibition, 53, 57
  - self-administration, 53, 57
  - strain differences
- $\Delta^9$ -Tetrahydrocannabinol, 171
  - beta-adrenoceptors
  - cardiovascular effects
  - chronic treatment
- Tetrahydro- $\beta$ -carboline, 1
  - drug discrimination
  - 5HT agonists
  - 5HT receptors
- Thermoregulation
  - capsaicin, 65
  - endogenous opioids, 95
  - footshock, 95
  - hyperthermia, 95
  - route of administration, 65
  - substance P, 65
  - Tween 80, 65
- Threshold determination, 311
  - d-amphetamine
  - brain stimulation reward
  - drug interactions
  - morphine
- Tobacco smoke refining, 305
  - cigarette smoking
  - human studies
  - nicotine intake
- Tolerance
  - central mechanism, 401
  - chronic administration, 401
  - cocaine, 401
  - discriminative stimulus properties, 401
  - haloperidol, 175
  - NaCl intake, 209
  - oral movement, 175
  - repeated administration, 209
  - reserpine, 209
  - treatment duration, 175
- Tolerance persistence, 105
  - alcohol preference
- ethanol
  - selective breeding
- Treatment duration, 175
  - haloperidol
  - oral movement
  - tolerance
- Tryptophan, 503
  - aggression
  - dose-dependent
  - monkeys
- Tween 80, 65
  - capsaicin
  - route of administration
  - substance P release
  - thermoregulation
- Tyr-MIF-1, 521
  - benzodiazepine receptor binding
  - GABA
  - in vivo
- Up-regulation, 477
  - apomorphine
  - D1 binding sites
  - D2 binding sites
  - stereotypy
- Uric acid, 381
  - amphetamine
  - ascorbic acid
  - in vivo voltammetry
  - serotonin depletion
  - uric acid
- Ventral tegmentum
  - amphetamine, 251
  - cue properties, 251, 261
  - differential effects, 261
  - discrimination, 261
  - dopaminergic/non-dopaminergic substrates, 251
  - electrical stimulation, 251, 261
  - haloperidol, 251
  - physostigmine, 261
- Word completion, 347
  - diazepam
  - free recall
  - human studies
  - memory, explicit
  - memory, implicit
  - neurological impairment
  - spared memory function
- Zimeldine, 367
  - depressive behavior
  - desipramine
  - neonatal exposure

## AUTHOR INDEX

- |                    |                       |                      |                       |
|--------------------|-----------------------|----------------------|-----------------------|
| Agmo, A., 47       | Bain, G. T., 311      | Behm, F., 305        | Bierkamper, G., 165   |
| Ali, S. F., 171    | Bardo, M. T., 267     | Belzung, C., 29      | Blaker, W. D., 157    |
| Altman, H. J., 353 | Bartness, T. J., 447  | Benvenha, M. J., 283 | Blanchard, D. C., 437 |
| Amit, Z., 335      | Bechara, A., 219, 227 | Bianchi, M., 385     | Blanchard, R. J., 437 |

Block, R. I., 7  
 Boja, J. W., 153  
 Boucke, K., 511  
 Branch, M. N., 375  
 Breese, G. R., 213  
 Brini, A., 385  
 Buckholtz, N. S., 179  
 Buterbaugh, G. G., 291  
  
 Calkins, D., 433  
 Cameron, D. L., 193  
 Cannon, D. S., 53, 57  
 Capacchione, J. F., 283  
 Carey, R. J., 203  
 Carrell, L. E., 53, 57  
 Caton, T. M., 495  
 Cawley, G., 469  
 Chamberlain, B., 503  
 Chapouthier, G., 29  
 Chipkin, R. E., 477  
 Cools, A., 453  
 Cooper, S. J., 187, 427  
 Crocker, A. D., 193  
  
 Danti, S., 321  
 Dawson, R., Jr., 165  
 De Kok, Y. J. M., 465  
 Delaney, D., 483  
 DeMeersman, R., 361  
 Desa, A., 187  
 Dib, B., 65  
 Divine, K. K., 495  
 Dodd, R. H., 29  
 Druhan, J. P., 251, 261  
  
 Eckerman, D. A., 213  
 Ellison, G. D., 175  
 Emmett-Oglesby, M. W., 401  
 Eriksson, P. S., 87  
 Ervin, F. R., 503  
 Etscorn, F., 495  
 Evans, E. B., 171  
  
 Falk, J. L., 209, 517  
 Fang, J. C., 347  
 Fernández, H., 47  
 Fibiger, H. C., 251, 261  
 Fischman, M. W., 459  
 Foltin, R. W., 459  
 Forster, M. J., 275  
 Fowles, D. C., 7  
 Fujiwara, M., 101  
 Furukawa, H., 411, 489  
  
 Gatto, G. J., 105, 111  
 Geiger, J. D., 419  
 Getty, D., 361  
 Geyer, M. A., 393  
 Ghoneim, M. M., 7, 347  
 Glennon, R. A., 39  
  
 Goodwin, S. D., 157  
 Graeff, F. G., 21  
 Grant, K. A., 81  
 Greenblatt, D. J., 521  
 Griffiths, R. R., 389  
 Gualtieri, C. T., 213  
  
 Hagen, L. S., 495  
 Harper, A. E., 525  
 Hashim, A., 299  
 Haskett, C., 381  
 Heinsbroek, R. P. W., 371  
 Hilakivi, I., 367  
 Hilakivi, L. A., 367  
 Hinrichs, J. V., 347  
 Hiramatsu, M., 411, 489  
 Holzhäuer-Oitzl, M.-S., 511  
 Hori, K., 437  
 Horita, A., 433  
 Hubner, C. B., 311  
 Hunt, T., 335  
 Huston, J. P., 511  
  
 Iorio, L. C., 477  
 Ishikawa, K., 411  
 Itoh, T., 35  
  
 Jenks, B. G., 465  
 Jerussi, T. P., 283  
 Johanson, C. E., 81  
  
 Kafiluddi, R., 171  
 Kameyama, T., 43, 411, 489  
 Kastin, A. J., 521  
 Kataoka, Y., 101  
 Kato, S., 407  
 Kennedy, R. H., 171  
 Kenney, S., 203  
 Kiyota, Y., 243  
 Kleven, M. S., 235  
 Kohori, I., 35  
 Kolasiewicz, W., 453  
 Kornetsky, C., 311  
 Kuczenski, R., 393  
 Kumar, V., 7  
 Kuribara, H., 209  
  
 Lai, H., 147, 433  
 Lajtha, A., 299  
 Lal, H., 275  
 Lamb, R. J., 389  
 Li, T.-K., 105, 111  
 Lister, R. G., 75  
 Lumeng, L., 105, 111  
  
 McBride, W. J., 105, 111  
 McQuade, R. D., 477  
 Manev, H., 443  
 Mann-Koepke, K., 213  
 Mantegazza, P., 385  
  
 Martin, P., 321  
 Martin-Iverson, M. T., 251, 261  
 Masuda, Y., 35  
 Middaugh, L. D., 179  
 Milani, H., 21  
 Miller, L. G., 521  
 Mine, K., 101  
 Misslin, R., 29  
 Miyamoto, M., 243  
 Mokler, D. J., 327  
 Moore, G. A., 495  
 Morgan, M. J., 95  
 Moya-Huff, F. A., 71  
 Mueller, K., 381  
 Murai, S., 35  
 Murphy, J. M., 105, 111  
 Murphy-Erdosh, C., 317  
 Muscat, R., 423  
  
 Nabeshima, T., 411, 489  
 Nagaoka, A., 243  
 Neisewander, J. L., 267  
 Niwa, M., 101  
 Normile, H. J., 353  
  
 Ossowska, K., 453  
  
 Panerai, A. E., 385  
 Paredes, R., 47  
 Pathak, D., 7  
 Paule, M. G., 171  
 Pearlson, G. D., 459  
 Pechnick, R. N., 95  
 Pedroso, J. J., 459  
 Pericic, D., 443  
 Perry, D. C., 15  
 Phillips, A. G., 251, 261  
 Pihl, R. O., 503  
 Poling, A., 483  
 Poncelet, M., 321  
  
 Rech, R. H., 327  
 Repa, J. J., 525  
 Retz, K. C., 275, 401  
 Rönnback, L., 87  
 Rose, J. E., 305  
 Rosecrans, J. A., 39  
 Rosengren, L., 87  
 Rothermel, S., 469  
 Russo, P. V., 393  
  
 Sacerdote, P., 385  
 Saito, H., 35  
 Sakurai, Y., 101  
 Sanders, D. L., 495  
 Sannerud, C. A., 389  
 Sant, W. W., 175  
 Scallet, A. C., 171  
 Schaal, D. W., 375  
 Schaefer, D. C., 361  
  
 Schechter, M. D., 1, 153  
 Schroeder, S. R., 213  
 Scott, E. P., 495  
 See, R. E., 175  
 Segal, D. S., 393  
 Segal, R., 335  
 Seifen, E., 171  
 Sershen, H., 299  
 Sherman, L. C., 327  
 Simon, P., 321  
 Slikker, W., Jr., 171  
 Smolen, A., 317  
 Smolen, T. N., 317  
 Soubrié, P., 321  
 Sparber, S. B., 235  
 Spoerlein, M. T., 341  
 Stoudt, K. W., 327  
  
 Tang, M., 209, 517  
 Tews, J. K., 525  
 Tom, P., 437  
 Towell, A., 423  
 Trimmer, C. K., 275  
  
 Ueki, S., 101  
 Ukai, M., 43  
  
 Van Abeelen, J. H. F., 465  
 Van Daal, J. H. H. M., 465  
 van de Poll, N. E., 371  
 Van Der Kooy, D., 219, 227  
 van Haaren, F., 371  
 VanderWende, C., 341  
 Vogel, E., 29  
  
 Wakasa, Y., 407  
 Waldbillig, R. J., 447  
 Waller, M. B., 105, 111  
 Wecker, L., 469  
 Wehner, J. M., 317  
 Wendelaar Bonga, S. E., 465  
 Westerberg, V. S., 419  
 Wilkie, D. M., 251, 261  
 Willner, P., 423  
 Willis, G. L., 197  
 Wilmot, C. A., 341  
 Wolfarth, S., 453  
 Wood, D. M., 401  
 Wronski, A., 87  
  
 Yamaguchi, K., 411  
 Yamashita, K., 101  
 Yanagita, T., 407  
 Yerbury, R. E., 427  
 Young, S. N., 503  
  
 Zabawska, J., 433  
 Zantvoord, F., 371  
 Zeuchner, J., 87  
 Zito, K. A., 219  
 Zucker, J., 433